Stromal remodeling and neoantigen clonality as used to evaluate benefit from SIRT–nivolumab in HCC.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Josepmaria Argemi, Sandra Hervas-Stubbs, Enrique Conde, Angel Martinez-Montes, Ziyi Li, Ibon Tamayo, Amy Cross, Josep M. Piulats, Ana Matilla, Mercedes Iñarrairaegui, Maria Varela, Manuel de la Torre, Maria Reig, Fadi Issa, Ankur Sharma, Florent Ginhoux, Isabel Fabregat, Carlos E. De Andrea, Pablo Sarobe, Bruno Sangro
Institutions: Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada, Garvan Institute of Medical Research, University of Oxford, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Hospital General Universitario Gregorio Marañón, Hospital Universitario Central de Asturias, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona, Singapore Immunology Network, Shanghai Institute of Immunology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162689437
Cites:
Cited by:
Related to: